{"id":42192,"date":"2025-09-24T14:59:29","date_gmt":"2025-09-24T06:59:29","guid":{"rendered":"https:\/\/flcube.com\/?p=42192"},"modified":"2025-09-24T14:59:30","modified_gmt":"2025-09-24T06:59:30","slug":"rm-bio%e2%80%91tech-secures-cde-approval-for-hf001-stem%e2%80%91cell-therapy-in-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42192","title":{"rendered":"RM\u202fBio\u2011Tech Secures CDE Approval for HF001 Stem\u2011Cell Therapy in Type\u202f2 Diabetes"},"content":{"rendered":"\n<p><strong>Beijing RM Bio\u2011Tech Co., Ltd.<\/strong> announced that the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has approved its <strong>Investigational New Drug (IND)<\/strong> application for <strong>HF001<\/strong>, an umbilical\u2011cord\u2011mesenchymal\u2011stem\u2011cell (UC\u2011MSC) injection, for the treatment of <strong>Type\u202f2 diabetes (T2D)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile\">Product Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HF001<\/strong> is a fully\u2011humanised, GMP\u2011grade UC\u2011MSC therapy derived from healthy donor umbilical\u2011cord tissue.<\/li>\n\n\n\n<li>The product is engineered to <strong>restore insulin\u2011secreting \u03b2\u2011cell mass<\/strong> and enhance peripheral insulin sensitivity, thereby reducing exogenous insulin requirements.<\/li>\n\n\n\n<li>Manufacturing leverages a scalable bioreactor platform, positioning RM\u202fBio\u2011Tech for rapid global expansion.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence\">Clinical Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Sample Size<\/th><th>Key Outcomes (48\u202fWeeks)<\/th><th>Clinical Significance<\/th><\/tr><\/thead><tbody><tr><td>Phase\u202fI\/II<\/td><td>120<\/td><td><strong>HbA1c reduction<\/strong>: 1.2\u202f%\u202f\u00b1\u202f0.3\u202f%<\/td><td>Demonstrates meaningful glycaemic improvement with a favourable safety profile.<\/td><\/tr><tr><td>Phase\u202fII<\/td><td>60<\/td><td><strong>Daily insulin dose<\/strong>: \u2193\u202f45\u202f%<\/td><td>Indicates potential for substantial cost savings and improved patient quality of life.<\/td><\/tr><tr><td>Safety<\/td><td>\u2014<\/td><td>No serious adverse events<\/td><td>Confirms the tolerability of UC\u2011MSC infusion.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CDE IND clearance<\/strong> removes the final regulatory hurdle before multinational phase\u2011III trials, slated to commence in Q1\u202f2026.<\/li>\n\n\n\n<li>The approval aligns with China\u2019s \u201cMade\u202fin\u202fChina\u202f2025\u201d initiative, prioritising innovative biotherapeutics and reinforcing RM\u202fBio\u2011Tech\u2019s position as a domestic leader in regenerative medicine.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The global T2D therapeutics market is projected to surpass <strong>$200\u202fbillion<\/strong> by 2030; stem\u2011cell therapies represent a high\u2011growth sub\u2011segment.<\/li>\n\n\n\n<li>HF001\u2019s unique mechanism\u2014direct \u03b2\u2011cell regeneration versus pharmacologic agents\u2014offers a differentiated value proposition to clinicians and payers.<\/li>\n\n\n\n<li>RM\u202fBio\u2011Tech is actively pursuing strategic collaborations with diabetes\u2011care platforms to accelerate co\u2011development, licensing, and distribution worldwide.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Beijing RM Bio\u2011Tech Co., Ltd. announced that the Center for Drug Evaluation (CDE) under the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":42194,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[77,62,39,4369],"class_list":["post-42192","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cell-therapy","tag-clinical-trial-approval-initiation","tag-diabetes","tag-rm-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>RM\u202fBio\u2011Tech Secures CDE Approval for HF001 Stem\u2011Cell Therapy in Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Beijing RM Bio\u2011Tech Co., Ltd. announced that the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for HF001, an umbilical\u2011cord\u2011mesenchymal\u2011stem\u2011cell (UC\u2011MSC) injection, for the treatment of Type\u202f2 diabetes (T2D).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=42192\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RM\u202fBio\u2011Tech Secures CDE Approval for HF001 Stem\u2011Cell Therapy in Type\u202f2 Diabetes\" \/>\n<meta property=\"og:description\" content=\"Beijing RM Bio\u2011Tech Co., Ltd. announced that the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for HF001, an umbilical\u2011cord\u2011mesenchymal\u2011stem\u2011cell (UC\u2011MSC) injection, for the treatment of Type\u202f2 diabetes (T2D).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=42192\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-24T06:59:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-24T06:59:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2406.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42192#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42192\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"RM\u202fBio\u2011Tech Secures CDE Approval for HF001 Stem\u2011Cell Therapy in Type\u202f2 Diabetes\",\"datePublished\":\"2025-09-24T06:59:29+00:00\",\"dateModified\":\"2025-09-24T06:59:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42192\"},\"wordCount\":282,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42192#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2406.webp\",\"keywords\":[\"Cell-therapy\",\"Clinical trial approval \\\/ initiation\",\"Diabetes\",\"RM Bio\u2011Tech\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42192#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42192\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=42192\",\"name\":\"RM\u202fBio\u2011Tech Secures CDE Approval for HF001 Stem\u2011Cell Therapy in Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42192#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42192#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2406.webp\",\"datePublished\":\"2025-09-24T06:59:29+00:00\",\"dateModified\":\"2025-09-24T06:59:30+00:00\",\"description\":\"Beijing RM Bio\u2011Tech Co., Ltd. announced that the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for HF001, an umbilical\u2011cord\u2011mesenchymal\u2011stem\u2011cell (UC\u2011MSC) injection, for the treatment of Type\u202f2 diabetes (T2D).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42192#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42192\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42192#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2406.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2406.webp\",\"width\":1080,\"height\":608,\"caption\":\"RM\u202fBio\u2011Tech Secures CDE Approval for HF001 Stem\u2011Cell Therapy in Type\u202f2 Diabetes\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42192#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RM\u202fBio\u2011Tech Secures CDE Approval for HF001 Stem\u2011Cell Therapy in Type\u202f2 Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"RM\u202fBio\u2011Tech Secures CDE Approval for HF001 Stem\u2011Cell Therapy in Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry","description":"Beijing RM Bio\u2011Tech Co., Ltd. announced that the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for HF001, an umbilical\u2011cord\u2011mesenchymal\u2011stem\u2011cell (UC\u2011MSC) injection, for the treatment of Type\u202f2 diabetes (T2D).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=42192","og_locale":"en_US","og_type":"article","og_title":"RM\u202fBio\u2011Tech Secures CDE Approval for HF001 Stem\u2011Cell Therapy in Type\u202f2 Diabetes","og_description":"Beijing RM Bio\u2011Tech Co., Ltd. announced that the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for HF001, an umbilical\u2011cord\u2011mesenchymal\u2011stem\u2011cell (UC\u2011MSC) injection, for the treatment of Type\u202f2 diabetes (T2D).","og_url":"https:\/\/flcube.com\/?p=42192","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-24T06:59:29+00:00","article_modified_time":"2025-09-24T06:59:30+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2406.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=42192#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=42192"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"RM\u202fBio\u2011Tech Secures CDE Approval for HF001 Stem\u2011Cell Therapy in Type\u202f2 Diabetes","datePublished":"2025-09-24T06:59:29+00:00","dateModified":"2025-09-24T06:59:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=42192"},"wordCount":282,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=42192#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2406.webp","keywords":["Cell-therapy","Clinical trial approval \/ initiation","Diabetes","RM Bio\u2011Tech"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=42192#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=42192","url":"https:\/\/flcube.com\/?p=42192","name":"RM\u202fBio\u2011Tech Secures CDE Approval for HF001 Stem\u2011Cell Therapy in Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=42192#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=42192#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2406.webp","datePublished":"2025-09-24T06:59:29+00:00","dateModified":"2025-09-24T06:59:30+00:00","description":"Beijing RM Bio\u2011Tech Co., Ltd. announced that the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for HF001, an umbilical\u2011cord\u2011mesenchymal\u2011stem\u2011cell (UC\u2011MSC) injection, for the treatment of Type\u202f2 diabetes (T2D).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=42192#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=42192"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=42192#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2406.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2406.webp","width":1080,"height":608,"caption":"RM\u202fBio\u2011Tech Secures CDE Approval for HF001 Stem\u2011Cell Therapy in Type\u202f2 Diabetes"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=42192#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"RM\u202fBio\u2011Tech Secures CDE Approval for HF001 Stem\u2011Cell Therapy in Type\u202f2 Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2406.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42192","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42192"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42192\/revisions"}],"predecessor-version":[{"id":42195,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42192\/revisions\/42195"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/42194"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42192"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42192"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42192"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}